PharmGen Science, Inc. (KRX:004720)
South Korea flag South Korea · Delayed Price · Currency is KRW
4,320.00
+20.00 (0.47%)
Feb 13, 2025, 9:00 AM KST

PharmGen Science Revenue

PharmGen Science had revenue of 41.65B KRW in the quarter ending September 30, 2024, with 1.22% growth. This brings the company's revenue in the last twelve months to 173.60B, up 9.08% year-over-year. In the year 2023, PharmGen Science had annual revenue of 166.78B with 10.50% growth.

Revenue (ttm)
173.60B
Revenue Growth
+9.08%
P/S Ratio
0.46
Revenue / Employee
683.46M
Employees
254
Market Cap
80.26B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2023166.78B15.85B10.50%
Dec 31, 2022150.93B41.06B37.38%
Dec 31, 2021109.87B13.25B13.72%
Dec 31, 202096.61B1.48B1.55%
Dec 31, 201995.14B6.04B6.77%
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro
Dec 31, 2014 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Samsung Biologics 4,364.39B
Celltrion 2,876.25B
SK Biopharmaceuticals 511.33B
Yuhan 2,008.84B
SK bioscience 201.30B
Hanmi Pharm. 1,495.50B
Hanmi Science 1,283.65B
Hanall Biopharma 134.24B
Revenue Rankings